Commencing a new series called Pioneers in Health Care, is an interview with Professor Jeremy Chapman AC who for over 30 years, has been involved in nephrectomy, or kidney transplantation.
Honoured “for eminent service to medicine, particularly in the areas of clinical and biomedical research, to the development of ethical policy and practices for organ donation, acquisition and transplantation, and to renal medicine organisations and publications, Jeremy Chapman AC has played significant roles in development of kidney, pancreas and unrelated Bone Marrow Transplantation in Australia.
He has been responsible for global development of ethical transplantation through The Transplantation Society, the World Marrow Donor Association and through advisory roles to the World Health Organisation. He is identified as one of the most influential global leaders in the field of clinical transplantation.
Credit: Australian Academy of Health and Medical Sciences
In September 2022, Western Sydney’s Professor Jeremy Chapman was bestowed the prestigious 2022 Medawar Prize on-stage in Buenos Aires, Argentina.
The Medawar Prize, awarded biennially since 1990 and named after Society co-founder Sir Peter Medawar, is globally recognised as the most prestigious award for excellence in Transplantation Science and Jeremy is “surprised and honoured” saying “not many people get this award so it’s a true delight”.
The award recognises outstanding investigators whose contributions have profoundly influenced organ transplantation.
Professor Chapman has dedicated much of his career to clinical care and research at Westmead, since commencing as a renal physician at Westmead Hospital in 1987. He has worked as Director of Western Renal Services, Westmead Hospital’s Director of Medicine and Cancer, as well as the Director of the Westmead Hospital Foundation, Chair of the Westmead Research Hub Council and member and deputy chair of the board of WSLHD.
In the early days of transplantation long-term care of transplant patients was mostly undertaken by transplant surgeons but as both the numbers and the complexity of transplantation increased, Professor Chapman was amongst the vanguard of renal physicians that focussed, as a physician, on care of patients after their transplant.
“It’s been an interesting road of discovery over time, but also a major transformation in the outcome for our patients,” Professor Chapman said.
“When I was first involved in 1978, we thought a 60% success rate at one year after a transplant was pretty good, even when choosing the very best patients to transplant, now, we would expect more than 90 or 95% success rates in much, much older and sicker patients.”
“Australia has been a great springboard for global activity, so it’s worked out very well to be working in Australia to impact on transplantation globally.”, according to Professor Chapman.
You Might also like
- 
					
					AHW Exhibitor: HPA Managing Director Shawn WighamHospital Products Australia (HPA) exhibited at last week’s Australian Healthcare Week. Anne Dao spoke with Managing Director Shawn Wigham on the advanced equipment HPA supply, that combines technology and furnishings within the clinical setting. 
 Post Views:
 3,524
- 
					
					AHHA Sidney Sax Medal 2019 Awarded to Vicki WadeAHHA Sidney Sax Medal 2019 awarded to Vicki Wade 
- 
					
					Developing the next generation of medicines to target and enhance the microbiomeAustralian Health Journal spoke to Associate Professor Sam Forster, Research Group Head 
 Microbiota and Systems Biology, Hudson Institute of Medical Research, Team Leader, Australian Microbiome Culture Collection & Chief Scientific Officer, BiomeBank and Dr Sam Costello, Co-Founder and CEO of BiomeBank about the microbiome, partnering and some of the breakthroughs in recent years.
 
		
		 
					
																 
					
																				
					